#1 Clinical Trials Search in Europe

Teprotumumab

Teprotumumab, also known as Tepezza, is a groundbreaking drug being studied in clinical trials for the treatment of Thyroid Eye Disease (TED). This article explores the various clinical trials investigating the efficacy, safety, and administration methods of teprotumumab in patients with TED and other conditions. We’ll delve into the drug’s potential benefits, its mechanism of action, and the ongoing research to optimize its use in medical practice.

Table of Contents

What is Teprotumumab?

Teprotumumab is a medication that has gained attention in the medical community for its potential in treating certain eye-related conditions. It’s also known by other names such as Tepezza, HZN-001, and RV 001[1][6]. Teprotumumab is classified as a monoclonal antibody, which is a type of protein designed to target specific cells in the body[5].

What Conditions Does Teprotumumab Treat?

Teprotumumab is primarily used to treat a condition called Thyroid Eye Disease (TED), also known as Graves’ Ophthalmopathy or Thyroid-Associated Ophthalmopathy[2][5][6]. TED is a rare autoimmune condition where the immune system attacks the muscles and tissues around the eyes, causing various symptoms.

Symptoms of TED that teprotumumab aims to address include:

  • Proptosis: Bulging of the eyes
  • Diplopia: Double vision
  • Eye pain and discomfort
  • Swelling and redness around the eyes
  • Difficulty closing the eyelids completely

In some cases, teprotumumab is also being studied for its potential in treating Diabetic Macular Edema (DME), a complication of diabetes that affects the eyes[3].

How Does Teprotumumab Work?

Teprotumumab works by targeting a specific protein in the body called the Insulin-like Growth Factor-1 Receptor (IGF-1R). This receptor is believed to play a role in the inflammatory process that occurs in Thyroid Eye Disease[6].

By blocking the IGF-1R, teprotumumab helps to:

  • Reduce inflammation in and around the eyes
  • Decrease the swelling of eye muscles and tissues
  • Potentially reverse some of the changes caused by TED, such as eye bulging and double vision

How is Teprotumumab Administered?

Teprotumumab is typically administered as an intravenous (IV) infusion. This means the medication is given directly into a vein. The treatment schedule usually involves:

  • Infusions every 3 weeks
  • A total of 8 infusions over a 24-week (6-month) period
  • The first dose is usually 10 mg/kg, followed by 20 mg/kg for the remaining doses[6]

Researchers are also exploring other methods of administration, including subcutaneous (under the skin) injections, which may be more convenient for some patients[1].

Current Clinical Trials and Research

Several clinical trials are ongoing to further study teprotumumab’s effectiveness and safety. These studies are looking at:

  • Different dosing schedules and durations of treatment[4]
  • The drug’s effects on various aspects of Thyroid Eye Disease[5]
  • Potential use in treating other eye conditions like Diabetic Macular Edema[3]
  • New methods of administration, such as subcutaneous injections[2]

Potential Side Effects and Safety Considerations

As with any medication, teprotumumab can cause side effects. Common side effects reported in clinical trials include:

  • Muscle spasms
  • Nausea
  • Hair loss
  • Diarrhea
  • Fatigue
  • High blood sugar (hyperglycemia)
  • Hearing problems

It’s important to note that not everyone experiences these side effects, and your doctor will monitor you closely during treatment[4].

Effectiveness of Teprotumumab

Clinical trials have shown promising results for teprotumumab in treating Thyroid Eye Disease. In one study:

  • 83% of patients receiving teprotumumab showed a significant reduction in eye bulging (proptosis) compared to only 10% in the placebo group
  • Improvements were often noticeable as early as 6 weeks into treatment
  • The drug showed positive effects on various symptoms of TED, including double vision and quality of life measures[6]

These results suggest that teprotumumab could potentially replace or reduce the need for surgery in many patients with Thyroid Eye Disease, even those with more advanced cases[5].

Aspect Details
Drug Name Teprotumumab (also known as Tepezza, RV 001, HZN-001)
Primary Condition Studied Thyroid Eye Disease (TED) / Graves’ Ophthalmopathy
Other Conditions Diabetic Macular Edema (DME)
Mechanism of Action Insulin-like growth factor-1 receptor (IGF-1R) inhibitor antibody
Administration Methods Intravenous (IV) infusion, Subcutaneous (SC) injection
Dosing Regimens Varies by trial; typically every 3 weeks, 4-16 infusions
Primary Outcomes Proptosis reduction, Clinical Activity Score improvement, Quality of Life changes
Safety Monitoring Treatment-emergent adverse events (TEAEs), laboratory tests, vital signs
Trial Phases Phase 1, Phase 1b, Phase 3b/4
Special Populations Studies include both non-Japanese and Japanese participants

FAQ

  • What is Teprotumumab and how does it work? Teprotumumab is a fully human monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R). It works by blocking the inflammatory and autoimmune processes that underlie Thyroid Eye Disease, potentially reversing symptoms such as proptosis (eye bulging) and diplopia (double vision).
  • What conditions is Teprotumumab being studied for in clinical trials? Teprotumumab is primarily being studied for Thyroid Eye Disease (TED), also known as Graves' Ophthalmopathy. Some trials are also investigating its potential use in other conditions such as Diabetic Macular Edema (DME).
  • How is Teprotumumab administered in clinical trials? In most trials, Teprotumumab is administered through intravenous (IV) infusion. Some studies are also exploring subcutaneous (SC) administration. The typical dosing regimen involves infusions every 3 weeks, with varying durations of treatment being investigated.
  • What are the main outcomes being measured in Teprotumumab clinical trials? The main outcomes being measured include changes in proptosis (eye bulging), Clinical Activity Score (CAS), quality of life scores, and safety parameters such as adverse events. Some trials also look at pharmacokinetics (how the drug moves through the body) and the need for retreatment.
  • Are there any side effects associated with Teprotumumab in clinical trials? While specific side effects are not detailed in the provided trial information, the studies are monitoring for treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI). Safety and tolerability are key aspects being evaluated in these clinical trials.

Ongoing Clinical Trials on Teprotumumab

  • A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

    Not yet recruiting

    1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study on the Safety and Tolerability of Teprotumumab for Patients with Thyroid Eye Disease

    Not recruiting

    1 1
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • Teprotumumab: A fully human monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R), used in the treatment of Thyroid Eye Disease.
  • Thyroid Eye Disease (TED): Also known as Graves' Ophthalmopathy, it is an autoimmune condition where immune cells attack the eye muscles and connective tissues, leading to symptoms like eye bulging, pain, and double vision.
  • Proptosis: The forward displacement or bulging of the eye from its normal position in the eye socket.
  • Clinical Activity Score (CAS): A scoring system used to evaluate the activity of Thyroid Eye Disease, considering factors such as pain, redness, and swelling.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Subcutaneous (SC) administration: A method of drug delivery where the medication is injected into the tissue layer between the skin and the muscle.
  • Intravenous (IV) infusion: A method of administering medication directly into a vein using a needle or catheter.
  • Diabetic Macular Edema (DME): A complication of diabetes that causes swelling in the macula, the part of the retina responsible for detailed central vision.
  • Treatment-emergent adverse events (TEAEs): Any unfavorable and unintended sign, symptom, or disease that appears or worsens after starting a medical treatment.
  • Graves' Ophthalmopathy: Another term for Thyroid Eye Disease, specifically associated with Graves' disease, an autoimmune disorder affecting the thyroid gland.

References

  1. https://clinicaltrials.gov/study/NCT06674941
  2. https://clinicaltrials.gov/study/NCT06389578
  3. https://clinicaltrials.gov/study/NCT02103283
  4. https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-teprotumumab-for-patients-with-thyroid-eye-disease/
  5. https://clinicaltrials.gov/study/NCT06275373
  6. https://clinicaltrials.gov/study/NCT01868997